Novel sustained-release drug delivery indwelling device for treating bladder cancer
By using a motor-driven drug delivery assembly and a limiting clamp design, the problem of inconvenience for patients to manually administer medication during bladder cancer treatment is solved, achieving automatic timed drug delivery and stable device fixation, thus improving the user experience.
Patent Information
- Application Number
- CN202423134517.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-18
- Publication Date
- 2026-02-03
- Estimated Expiration
- 2034-12-18
AI Technical Summary
In current bladder cancer treatments, indwelling drug delivery devices require manual operation by the patient, making them inconvenient to use.
A novel sustained-release drug delivery device was designed, comprising a motor-driven drug delivery assembly and a limiting clamp. The device automatically delivers drugs by moving the push plate through the screw and sleeve driven by the motor, and the container is fixed by the limiting clamp and adhesive to ensure stable use.
It enables automatic timed drug administration to patients, avoiding container movement and shaking, and improving stability and convenience of use.
Smart Images
Figure CN223861161U_ABST
Abstract
Description
Technical Field
[0001] This utility model relates to the field of medical device technology, specifically a novel sustained-release drug delivery device for treating bladder cancer. Background Technology
[0002] Bladder cancer is a malignant tumor that occurs on the bladder mucosa. Treatment often requires long-term, quantitative medication to ensure the effectiveness of the treatment.
[0003] In the treatment of bladder cancer, an indwelling drug delivery device is needed to administer medication to the patient at regular intervals. However, the patient needs to manually administer the medication using this device, which makes the process inconvenient. Utility Model Content
[0004] To address the shortcomings of existing technologies, this invention provides a novel sustained-release drug delivery device for the treatment of bladder cancer, which has the advantages of automatic drug delivery to patients and solves the problem of requiring patients to manually administer drugs.
[0005] This invention discloses a novel sustained-release drug delivery device for treating bladder cancer, comprising a drug delivery body, a controller located on the right side of the top of the drug delivery body, a groove formed on the left side of the top of the drug delivery body, a drug delivery assembly located within the inner cavity of the groove, the drug delivery assembly including a motor, the motor being fixedly connected to one end of the inner cavity of the groove, a screw at the output end of the motor, a threaded sleeve connected to the surface of the screw, a push plate fixedly fitted onto the surface of the threaded sleeve, a slider at the bottom of the push plate, a groove adapted to the slider formed at the bottom of the inner cavity of the groove, and a fixing assembly located at the other end of the top left side of the drug delivery body. The primary function of this invention is drug storage. Inside the container, the container is then fixed to the indwelling medication body by a fixing component. At this time, the output end of the container is fixed at the patient's medication site. When timed medication is required, the controller fixes the motor to run, the motor drives the screw to rotate, the screw drives the screw sleeve to move, the screw sleeve drives the push plate to move, and the slide and slider in the groove cooperate with the push plate to move. The push plate pushes the container to deliver the medication to the patient. When the medication is delivered to the required dose, the controller stops the motor. (The container mentioned in the text is a common syringe on the market. The specific structure of the syringe is common knowledge to those skilled in the art, so there is no need to describe the specific principle in detail.)
[0006] This invention relates to a novel sustained-release drug delivery device for treating bladder cancer. The fixing component includes a limiting plate, the bottom of which is connected to the other end of the top left side of the drug delivery body. A concave plate is fixedly connected to the center of the top of the limiting plate. An electric push rod is provided at the top of the inner cavity of the concave plate, and a limiting clamp is provided at the output end of the electric push rod. When the container needs to be fixed, it is first placed on the limiting plate. Then, the electric push rod is moved by the controller, causing the limiting clamp to move downwards. When the limiting clamp contacts the container, it engages with the limiting plate to fix the container, preventing movement during use and thus avoiding instability.
[0007] This invention relates to a novel sustained-release drug delivery device for treating bladder cancer. Both ends of the limiting plate are fixedly connected to mounting plates, and the inner cavity of the mounting plates is fixedly connected to the drug delivery body via mounting rods. The mounting plates and mounting rods effectively fix the limiting plate, improving its performance during use and preventing wobbling that could lead to instability in the components on the limiting plate.
[0008] This invention relates to a novel sustained-release drug delivery device for treating bladder cancer, wherein the end of the screw furthest from the motor is rotatably connected to a movable shaft, and the other end of the movable shaft is fixedly connected to a groove. The movable shaft can stabilize the rotation of the screw during rotation, preventing jamming.
[0009] This invention relates to a novel sustained-release drug delivery device for treating bladder cancer. The drug delivery device has adhesive tape on both sides of its bottom, with a tape length of not less than 20 centimeters. The adhesive tape can fix the drug delivery device to the patient's body, and the specific fixing position can be specified according to actual needs, making it convenient for the patient to keep the drug delivery device on their body.
[0010] This invention relates to a novel sustained-release drug delivery device for treating bladder cancer, wherein the output terminal of the controller is electrically connected to a motor, and the output terminal of the controller is electrically connected to an electric push rod.
[0011] Compared with the prior art, the beneficial effects of this utility model are as follows:
[0012] 1. The primary drug in this invention is stored in a container, which is then fixed to the indwelling drug administration body by a fixing component. At this time, the output end of the container is fixed at the patient's drug administration site. When timed drug administration is required, the controller fixes the motor to run, which drives the screw to rotate. The screw drives the screw sleeve to move, which in turn drives the push plate to move. The push plate moves through the groove and slider in the groove, and pushes the container to deliver the drug solution to the patient. When the required dose of drug solution is delivered, the controller stops the motor. (The container mentioned in this article is a common syringe on the market. The specific structure of the syringe is common knowledge to those skilled in the art, so there is no need to describe the specific principle in detail.)
[0013] 2. When it is necessary to fix the container, the container is first placed on the limiting plate. At this time, the electric push rod is moved by the controller. The electric push rod drives the limiting clamp to move downward. When the limiting clamp contacts the container, the limiting clamp cooperates with the limiting plate to fix the container. This avoids the container from moving during use, which would lead to instability in the use of the container.
[0014] The mounting plate and mounting rod can fix the limiting plate, which makes the limiting plate more effective during use and avoids the limiting plate shaking during use, which would lead to the instability of the components on the limiting plate.
[0015] The movable shaft can stabilize the screw rotation, preventing jamming during screw rotation.
[0016] By using adhesive tape, the medication administration device can be fixed to the patient's body. The specific fixing position can be specified according to actual needs, making it convenient for the patient to keep the medication administration device on their body. Attached Figure Description
[0017] The accompanying drawings, which are included to provide a further understanding of this application and form part of this application, illustrate exemplary embodiments and are used to explain this application, but do not constitute an undue limitation of this application. In the drawings:
[0018] Figure 1 This is a schematic diagram of the structure of this utility model;
[0019] Figure 2 This is a partial cross-sectional view of the main body for drug delivery of this utility model;
[0020] Figure 3 This is a schematic diagram of the drug delivery component of this utility model;
[0021] Figure 4 This is a schematic diagram of the fixing component structure of this utility model;
[0022] Figure 5 This is a partial cross-sectional view of the concave plate of this utility model.
[0023] In the diagram: 1. Indwelling drug administration body; 2. Controller; 3. Groove; 4. Drug delivery assembly; 401. Motor; 402. Slider; 403. Movable shaft; 404. Screw; 405. Screw sleeve; 406. Push plate; 5. Fixing assembly; 501. Limiting plate; 502. Mounting plate; 503. Mounting rod; 504. Concave plate; 505. Electric push rod; 506. Limiting clamp; 6. Adhesive; 7. Slide groove. Detailed Implementation
[0024] The following drawings will disclose several embodiments of this utility model. For clarity, many practical details will be described in the following description. However, it should be understood that these practical details should not be used to limit this utility model. That is, in some embodiments of this utility model, these practical details are not essential. In addition, for the sake of simplicity, some conventional structures and components will be shown in the drawings in a simple schematic manner.
[0025] Please see Figure 1-5 This invention relates to a novel sustained-release drug delivery device for treating bladder cancer, comprising a drug delivery body 1, a controller 2 located on the right side of the top of the drug delivery body 1, a groove 3 on the left side of the top of the drug delivery body 1, a drug delivery assembly 4 located within the cavity of the groove 3, the drug delivery assembly 4 including a motor 401, the motor 401 being fixedly connected to one end of the cavity of the groove 3, a screw 404 located at the output end of the motor 401, a threaded sleeve 405 threaded onto the surface of the screw 404, a push plate 406 fixedly fitted onto the surface of the threaded sleeve 405, a slider 402 located at the bottom of the push plate 406, a groove 7 adapted to the slider 402 located at the bottom of the cavity of the groove 3, and a fixing assembly 5 located at the other end of the top left side of the drug delivery body 1. The invention primarily stores the drug in a container, and then... The container is fixed to the indwelling medication body 1 by the fixing component 5. At this time, the output end of the container is fixed at the patient's medication site. When timed medication is required, the controller 2 fixes the motor 401 to run. The motor 401 drives the screw 404 to rotate. The screw 404 drives the screw sleeve 405 to move. The screw sleeve 405 drives the push plate 406 to move. The sliding groove 7 and the slider 402 in the groove 3 cooperate with the push plate 406 to move. The push plate 406 pushes the container to deliver the medication to the patient. When the medication is delivered to the required dose, the controller 2 controls the motor 401 to stop running. (The container mentioned in the text is a common syringe on the market. The specific structure of the syringe is common knowledge to those skilled in the art, so there is no need to describe the specific principle in detail.)
[0026] The fixing component 5 includes a limiting plate 501. The bottom of the limiting plate 501 is connected to the other end of the top left side of the drug administration indwelling body 1. A concave plate 504 is fixedly connected to the center of the top of the limiting plate 501. An electric push rod 505 is provided at the top of the inner cavity of the concave plate 504. A limiting clamp 506 is provided at the output end of the electric push rod 505. When it is necessary to fix the container, the container is first placed on the limiting plate 501. At this time, the electric push rod 505 is moved by the controller 2. The electric push rod 505 drives the limiting clamp 506 to move downward. When the limiting clamp 506 contacts the container, the container can be fixed by the cooperation between the limiting clamp 506 and the limiting plate 501, so as to avoid the container moving during use and thus the instability of the container.
[0027] Mounting plates 502 are fixedly connected to both ends of the limiting plate 501, and the inner cavity of the mounting plate 502 is fixedly connected to the drug administration indwelling body 1 through the mounting rod 503. The mounting plate 502 and the mounting rod 503 can fix the limiting plate 501, so that the limiting plate 501 is more effective when in use and avoids the limiting plate 501 from shaking during use, which would lead to the instability of the components on the limiting plate 501.
[0028] The end of the screw 404 away from the motor 401 is rotatably connected to a movable shaft 403, and the other end of the movable shaft 403 is fixedly connected to the groove 3. The movable shaft 403 can stabilize the rotation of the screw 404 when it rotates, thus preventing the screw 404 from getting stuck.
[0029] The drug administration indwelling body 1 has adhesive tape 6 on both sides of its bottom, and the length of the adhesive tape 6 is not less than 20 centimeters. The drug administration indwelling body 1 can be fixed to the patient through the adhesive tape 6. The specific fixing position can be specified according to actual needs, so as to facilitate the patient to keep the drug administration indwelling body 1 on their body.
[0030] The output of controller 2 is electrically connected to motor 401, and the output of controller 2 is electrically connected to electric push rod 505.
[0031] When using this utility model: First, the drug is stored in the container, and then the container is fixed to the drug administration indwelling body 1 by the fixing component 5. At this time, the output end of the container is fixed at the patient's drug administration site. When timed drug administration is required, the controller 2 fixes the motor 401 to run, the motor 401 drives the screw 404 to rotate, the screw 404 drives the screw sleeve 405 to move, the screw sleeve 405 drives the push plate 406 to move, and the sliding groove 7 in the groove 3 and the slider 402 cooperate with the push plate 406 to move. The push plate 406 pushes the container to deliver the drug solution to the patient. When the drug solution is delivered to the required dose, the controller 2 controls the motor 401 to stop running. (The container mentioned in the text is a common syringe on the market. The specific structure of the syringe is common knowledge to those skilled in the art, so there is no need to describe the specific principle in detail.)
[0032] When it is necessary to fix the container, the container is first placed on the limiting plate 501. At this time, the controller 2 controls the electric push rod 505 to move. The electric push rod 505 drives the limiting clamp 506 to move downward. When the limiting clamp 506 contacts the container, the limiting clamp 506 cooperates with the limiting plate 501 to fix the container, thus avoiding the container from moving during use and thus preventing the container from becoming unstable.
[0033] The above description is merely an embodiment of this utility model and is not intended to limit the scope of this utility model. Various modifications and variations can be made to this utility model by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principle of this utility model should be included within the scope of the claims of this utility model.
Claims
1. A novel sustained-release drug delivery device for treating bladder cancer, comprising a drug delivery body (1), characterized in that: A controller (2) is provided on the right side of the top of the drug administration indwelling body (1). A groove (3) is provided on the left side of the top of the drug administration indwelling body (1). A drug pushing component (4) is provided in the inner cavity of the groove (3). The drug pushing component (4) includes a motor (401). The motor (401) is fixedly connected to one end of the inner cavity of the groove (3). A screw (404) is provided at the output end of the motor (401). A screw sleeve (405) is threadedly connected to the surface of the screw (404). A push plate (406) is fixedly sleeved on the surface of the screw sleeve (405). A slider (402) is provided at the bottom of the push plate (406). A sliding groove (7) adapted to the slider (402) is provided at the bottom of the inner cavity of the groove (3). A fixing component (5) is provided at the other end of the top left side of the drug administration indwelling body (1).
2. The novel sustained-release drug delivery device for treating bladder cancer according to claim 1, characterized in that: The fixing component (5) includes a limiting plate (501), the bottom of which is connected to the other end of the top left side of the drug administration indwelling body (1). A concave plate (504) is fixedly connected to the center of the top of the limiting plate (501). An electric push rod (505) is provided at the top of the inner cavity of the concave plate (504), and a limiting clamp (506) is provided at the output end of the electric push rod (505).
3. A novel sustained-release drug delivery device for treating bladder cancer according to claim 2, characterized in that: Both ends of the limiting plate (501) are fixedly connected to the mounting plate (502), and the inner cavity of the mounting plate (502) is fixedly connected to the drug administration indwelling body (1) through the mounting rod (503).
4. A novel sustained-release drug delivery device for treating bladder cancer according to claim 1, characterized in that: The screw (404) is rotatably connected to a movable shaft (403) at one end away from the motor (401), and the other end of the movable shaft (403) is fixedly connected to the groove (3).
5. A novel sustained-release drug delivery device for treating bladder cancer according to claim 1, characterized in that: Both sides of the bottom of the drug administration indwelling body (1) are provided with adhesive tape (6), and the length of the adhesive tape (6) is not less than 20 centimeters.
6. A novel sustained-release drug delivery device for treating bladder cancer according to claim 1, characterized in that: The output terminal of the controller (2) is electrically connected to the motor (401), and the output terminal of the controller (2) is electrically connected to the electric push rod (505).